Navigation Links
Treatment With VP20621 (Non-Toxigenic Clostridium difficile; NTCD) In A Phase 2 Study Resulted In High Rates Of Colonization And Statistically Significant Reductions In Recurrence Of C. difficile Infection
Date:4/22/2013

ackage inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward Looking Statements
Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward-looking statements in this press release include statements regarding potential therapeutic indication and use, safety, efficacy, tolerability and potential of VP20621, statements that VP20621 may prevent infection by toxin-producing strains of C. difficile and how colonization rates may be increased further. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. The development and commercialization of pharmaceutical products is subject to risks and uncertainties. The safety, colonization and efficacy data described in this press release are preliminary and additional review of the data may reveal additional findings which may not be consistent with this press release. The studies described in this press release represent the results of a Phase 2 study with VP20621 and the results of the study may not be predictive of how VP20621 will perform in future studies. There can be no assurance that that The FDA or EMA may view the data regarding VP20621 as insufficient or inconclusive, request additional data, require additional clinical studies, del
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel ... GPM Pediatrics, reacts to a recent study, which shows how ... Photo - http://photos.prnewswire.com/prnh/20140723/129709 According to ... severe stress are more likely than others to grow up ... pregnancy." There were two specific types of stress ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals Holdings ... that will be added to Parnell,s already extensive ... Pty Ltd, a biotechnology company. The compounds now ... shown promise in bone regeneration and dermal regeneration, ... the compounds for the veterinary market with the ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3
... Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) ... sponsored by scientists at the U.S. Department of,Energy,s ... leads to rapid weight loss and reduced food ... 20, 2008 in the journal Synapse, a,prestigious peer-reviewed ...
... MONTREAL, Aug. 20 Enobia Pharma, an emerging ... bone,disorders, today announced that the first patient in ... is investigating Enzyme,Replacement Therapy (ERT) with ENB-0040 for ... bone disorder for which there is no approved,treatment., ...
Cached Medicine Technology:Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss 2Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss 3Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 2Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 3
(Date:7/26/2014)... 2014 The European Artificial lift market report ... analysis and forecast of revenue. The artificial lift market in ... 2013 to around $5.4 billion by 2018, at a CAGR ... the TOC of European artificial lift market report, to get ... glimpse of the segmentation in European Artificial lift market, and ...
(Date:7/26/2014)... Recently, iFitDress.com, a popular supplier of wedding dresses and ... range of high quality party outfits. Additionally, it has ... they are now provided at discounted prices, up to ... the leading suppliers in the international market. According to ... dresses have flattering looks and fine craftsmanship. They ...
(Date:7/26/2014)... News) -- Pools can provide much-needed relief from the ... they swallow too much chlorinated water, experts warn. ... ones to get water in their mouth. Some kids ... warnings from their parents. Although swallowing a small ... parents to realize that ingesting too much can lead ...
(Date:7/26/2014)... 2014 As reported by Lauren ... based on 3 factors: smaller spaces, multi-generational access, and ... trend of 2014 lists, including this article on ... Amerec , a leading manufacturer of steam bath generators, ... due to smaller spaces and an effort to reduce ...
(Date:7/26/2014)... New York, NY (PRWEB) July 26, 2014 ... by Infosecurity magazine on July 23rd, new research by ... are starting to rewrite their playbook, now focusing more ... individuals en masse who have become increasingly wise to ... (GDF) founder and CEO/CTO, Joe Caruso, talks about ...
Breaking Medicine News(10 mins):Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:High Quality Wholesale Party Dresses Online at iFitDress.com 2Health News:Don't Let Kids Drink Pool Water 2Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 4Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 5Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 6
... April 3 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,Corp. (NASDAQ: NCST ... will,step down as Vice President Finance & Administration and ... another company in a field,unrelated to any of NUCRYST,s ... search for Mr. Lurier,s successor., "On behalf of ...
... April 3 /PRNewswire-FirstCall/ - SXC Health Solutions, Corp.,("SXC" or ... leading provider of,pharmacy benefits management services, announces that Mark ... CFO, will present at the,SunTrust 37th Annual Institutional Conference ... place on Tuesday, April 15,2008 at 9:40 am Eastern ...
... FRANCISCO, Calif., April 3, 2008 ,Renovis, Inc. (Nasdaq: ... the,discovery and development of drugs for major medical ... announced today that the waiting,period under the Hart-Scott-Rodino ... without the United States Federal Trade Commission,requesting additional ...
... 2008 Medical Records Institute (MRI),announces a new ... will be announced at the TEPR 2008 opening ... This new TEPR Award is the first ... their products meet a range of EMR medicolegal,requirements, ...
... half just occasionally had too much , , THURSDAY, April 3 ... are habitual drinkers, but new research suggests that people who ... who drive while intoxicated. , When it comes to drunk ... said study author Dr. Nicole T. Flowers, a medical epidemiologist ...
... Lubbock, TX April 3, 2008 Patients with genital ... served by healthcare providers who initiate positive discussions about them, ... Womens Health. , Yet, too often, such discussions ... related to the piercings, due to healthcare providers uneasiness over ...
Cached Medicine News:Health News:NUCRYST Announces Senior Management Change 2Health News:NUCRYST Announces Senior Management Change 3Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 2Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 3Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 4Health News:Medical Records Institute Announces New TEPR Award for EMRs Best Meeting Medicolegal Requirements 2Health News:Alcoholics Not to Blame for All Drunk Driving Cases 2
... Radiopaque Bone Cement consists of ... sterile,ampule containing bone cement liquid ... a sterile polyethylene bag,containing bone ... pouch. The interiors of the ...
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
A "doughy" type of bone cement intended for manual application....
... technology, such as a recessed scratch-resistant sapphire ... housings, this arthroscope has superior clarity and ... Steris and steam autoclaving or soaked in ... to fit ACMI, Wolf, Dyonics and Storz ...
Medicine Products: